Fabio C Tucci

This inventor holds 20 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Neurocrine Biosciences, Inc., Epigen Biosciences, Inc., Bruin Biosciences, Inc.. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fabio C Tucci. Retrieved from https://idiyas.com/inventor/fabio-c-tucci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 5.7

ph-index = 7

Forward Citations = 135(Granted Patents)

Company Filing History:

10 out of 123

Neurocrine Biosciences, Inc.

patents

6 out of 6

Epigen Biosciences, Inc.

patents

2 out of 2

Bruin Biosciences, Inc.

patents

4. 2 out of 5

Curtana Pharmaceuticals, Inc.

patents

5. 2 out of 16,048

University of California

patents

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

Chemoembolization Agents

Pyrimidine Compounds

Pyridine Compounds

Disease Treatment

Heterocyclic Compounds

Olig2 Activity

Gonadotropin-Releasing Hormone

Receptor Antagonists

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12357570 - Chemoembolization agents (2025-07-15),

2. 12234224 - Pyrimidine and pyridine amine compounds and usage thereof in disease treatment (2025-02-25),

3. 11866421 - Pyrimidine and pyridine amine compounds and usage thereof in disease treatment (2024-01-09),

4. 11712418 - Chemoembolization agents (2023-08-01),

5. 11691951 - Inhibition of Olig2 activity (2023-07-04),

6. 11427552 - Heterocyclic compounds useful in the treatment of disease (2022-08-30),

7. 10570103 - Heterocyclic compounds useful in the treatment of disease (2020-02-25),

8. 10526298 - Heterocyclic compounds useful in the treatment of disease (2020-01-07),

9. 10227333 - Inhibition of OLIG2 activity (2019-03-12),

10. 10000459 - Heterocyclic compounds useful in the treatment of disease (2018-06-19),

11. 7462625 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto (2008-12-09),

12. 7419983 - Gonadotropin-releasing hormone receptor antagonists and methods related thereto (2008-09-02),

13. 7179815 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto (2007-02-20),

14. 7176211 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto (2007-02-13),

15. 7056927 - Gonadotropin-releasing hormone receptor antagonists and methods relating thereto (2006-06-06),

Title: The Innovative Journey of Fabio C Tucci

Introduction:

Fabio C Tucci is a visionary inventor based in San Diego, California, known for his groundbreaking contributions to the field of technology and beyond.

Latest Patents:

Fabio C Tucci holds several patents in various industries, including telecommunications, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative spirit.

Career Highlights:

With a career spanning over two decades, Fabio C Tucci has consistently pushed the boundaries of what is possible, leading teams to develop cutting-edge solutions that have revolutionized their respective fields.

Collaborations:

Throughout his career, Fabio C Tucci has collaborated with leading researchers, engineers, and scientists, fostering a culture of innovation and excellence that has resulted in numerous successful projects and products.

Conclusion:

In conclusion, Fabio C Tucci's relentless pursuit of innovation and his passion for creating a better future through technology make him a true pioneer in the world of inventions. His impact will continue to inspire generations to come.

Profile summary based on public USPTO records.